India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
The data highlights its RSV vaccine cuts hospitalizations in older adults
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Subscribe To Our Newsletter & Stay Updated
